Deal snapshot: Centene to Divest Two Pharmacy Businesses for USD 2.8bn Upfront.

MANews-(C)2009-2022

US-based health insurer Centene Corp. (NYSE: CNC) has signed a definitive agreement to sell its Magellan Rx pharmacy solutions organization to Prime Therapeutics LLC and a separate definitive agreement to sell its PantheRx Rare specialty and rare pharmacies business to a consortium of The Vistria Group, General Atlantic, and Nautic Partners, the company said.

Subject to customary purchase price adjustments, Centene expects to receive...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT